Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

GE to Acquire Leading Manufacturer of Cell Culture Products

By BiotechDaily International staff writers
Posted on 22 Aug 2011
A developer and supplier of cell culture media for biomedical research and the fast-growing biopharmaceutical and vaccine-manufacturing industry is being acquired by GE, one of the world’s largest manufacturers of biomedical equipment and supplies.

PAA Laboratories (Pasching, Austria) recently announced that it is the final stages of becoming part of GE Healthcare (Little Chalfont, United Kingdom), a unit of General Electric Company (Fairfield, CT, USA).

PAA Laboratories develops and manufactures specialized and innovative cell culture products such as media, sera, growth supplements, and reagents for use in biomedical research and in the production of protein-based pharmaceuticals. The global demand for media, sera, and reagents for cell culture is predicted to grow from $2.3 billion in 2009 to an estimated $3.9 billion by 2015. PAA Laboratories, which maintains manufacturing facilities registered with the [US] Food and Drug Administration (FDA), has recently inaugurated an advanced manufacturing facility for powdered cell culture media to meet the growing demand for these products from the biopharmaceutical industry.

The acquisition of PAA Laboratories, which is expected to be completed in the third quarter of 2011, is consistent with GE's strategy to invest in high technology, innovative businesses that deliver strong top-line growth and expanded margins. “The acquisition of PAA Laboratories is a significant step forward for our Life Sciences business and for biopharmaceutical manufacturing globally,” said Kieran Murphy, president and CEO of GE Healthcare Life Sciences. “GE Healthcare Life Sciences is well known for its expertise in the “downstream” processes of biopharmaceutical manufacturing. Adding “upstream” capabilities will enable us to provide an end-to-end, fully integrated service to our customers. We believe that an integrated approach, where we can help customers optimize every stage of their manufacturing process, has the potential to reduce cost of entry, deliver higher yields of finished product, and reduce time to market.”

Rainer Burian, CEO of PAA Laboratories said, “This is a great opportunity for the professional team of staff at PAA Laboratories, and we are very excited to become part of GE Healthcare’s Life Sciences business. The Board of Directors of PAA Laboratories strongly believes that joining such a well-respected and recognized organization will give us significant opportunities to grow our business further with new technologies, products, and services. The entire PAA Laboratories team looks forward to joining GE.”

Related Links:
PAA Laboratories
GE Healthcare
General Electric Company


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.